Contact: Don Geer, Marketing Manager 
Telephone: (518) 798-1215, Ext. 167

AngioDynamics Announces Agreement with Transonic Systems Corporation

Queensbury, NY; December 13, 2002 - AngioDynamics, Inc., a wholly owned subsidiary of E-Z-EM, 
Inc., (AMEX:EZM) today announced that it has entered into a worldwide agreement with Transonic 
Systems Corporation for distribution of the Transonic Endovascular Flowmeter System. The system 
will be marketed under the AngioDynamics brand name, and consists of the AngioDynamics 
FlowmeterÔ and the Reo-CathÔ Dilution Flow Catheter. Under the terms of the five-year agreement, 
AngioDynamics will distribute both products globally with exclusive rights in the United States. 
The products have been previously cleared by the U.S. Food and Drug Administration and comparable 
foreign agencies. 

The AngioDynamics FlowmeterÔ System measures flow rates in the bloodstream, providing physicians 
with the means to monitor the success of interventional vascular procedures such as hemodialysis 
catheter placement, stenting procedures, and peripheral balloon angioplasty. For the first time 
interventionalists will have detailed information concerning flow rates within the body and 
provides a much needed tool to assure procedural quality.

Commenting on the agreement, Cornelius Drost, Founder and President of Transonic Systems said, 
"This relationship combines Transonic Systems’ strength in hemodynamic flow meters with 
AngioDynamics’ marketing expertise in interventional radiology. Flow has long been documented in 
the hemodialysis clinics using our system as an important predictor of graft failure. 
AngioDynamics can now help extend the application of flow measurement into the radiology suite."

Commenting on the announcement, Eamonn P. Hobbs, President and CEO for AngioDynamics said, "The 
AngioDynamics FlowmeterÔ System is an innovative diagnostic tool that we believe will be 
essential to successful vascular access management in the future. As one of the leading 
suppliers of dialysis catheters in the United States, AngioDynamics is well positioned to bring 
this important new tool to our customers. We are excited to be working with Transonic Systems 
in what we hope will be a long and mutually rewarding relationship."

For additional information, please contact Don Geer at 1-800-772-6446 x167, or at 
dgeer@angiodynamics.com, or visit the AngioDynamics web site at www.angiodynamics.com. 

About E-Z-EM

E-Z-EM, Inc. (www.ezem.com) is a leading supplier of products used by radiologists, 
gastroenterologists and speech language pathologists for the diagnostic imaging of diseases and 
disorders of the GI tract, ranging from swallowing disorders (dysphagia) to colorectal cancers. 
E-Z-EM also is a third-party contract manufacturer of diagnostic contrast media, pharmaceuticals, 
non-prescription healthcare products, and defense decontaminants.

About AngioDynamics

AngioDynamics, Inc. (www.angiodynamics.com) is a leading supplier of products used by 
interventional radiologists and other physicians for the minimally invasive diagnosis and 
therapeutic treatment of peripheral vascular disease.

The statements made in this document contain certain forward-looking statements that involve a 
number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans", 
"believes", "seeks", "estimates," or variations of such words and similar expressions, are 
intended to identify such forward-looking statements. Investors are cautioned that actual events 
or results may differ from the Company’s expectations. In addition to the matters described 
above, the ability of the Company to develop its products, future actions by the FDA or other 
regulatory agencies, results of pending or future clinical trials, overall economic conditions, 
general market conditions, market acceptance, foreign currency exchange rate fluctuations, the 
effects on pricing from Group Purchasing Organizations, competition, including alternative 
procedures which continue to replace traditional fluoroscopic procedures, as well as the risk 
factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited 
to its Form 10-Q for the quarter ended August 31, 2002, as well as its Annual Report on Form 
10-K for the year ended June 1, 2002, may affect the actual results achieved by the Company.

End